Qualitative Concept
GSK Terminates Development of HBV Therapeutic Vaccine Due to Efficacy Failure
GSK, HBV, therapeutic vaccine, efficacy failure, clinical trial termination
GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC
GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships
Biocon Biologics Secures FDA Approval for YESINTEK, a Biosimilar to Stelara
Biocon Biologics, FDA approval, YESINTEK, Stelara biosimilar, ustekinumab, inflammatory diseases
GSK Terminates Hepatitis B Vaccine Trial Due to Efficacy Shortfalls
GSK, Hepatitis B Vaccine, Clinical Trial Termination, Efficacy Issues
Pragmatic Clinical Trials: Bridging the Gap Between Research and Real-World Practice
1. Pragmatic Clinical Trials, 2. Real-World Evidence, 3. Clinical Trial Design, 4. Effectiveness Research, 5. Healthcare Decision Making
Outlook Therapeutics to Resubmit BLA for ONS-5010 Despite Missing Primary Endpoint in NORSE EIGHT Trial
Outlook Therapeutics, ONS-5010, Lytenava, Wet Age-Related Macular Degeneration (wet AMD), Biologics License Application (BLA), NORSE EIGHT Trial, FDA Approval
FDA Approves BridgeBio’s Attruby for ATTR-CM, Offering New Hope for Patients
Attruby, BridgeBio, ATTR-CM, FDA approval, transthyretin amyloid cardiomyopathy, acoramidis, TTR stabilizer
Adragos Pharma Expands Global Reach with Acquisition of Swiss CDMO Baccinex
Adragos Pharma, Baccinex, CDMO, aseptic fill-finish, sterile drug production, pharmaceutical manufacturing
FDA Approves Attruby (Acoramidis) for ATTR-CM, Offering New Hope for Patients with Transthyretin Cardiac Amyloidosis
Attruby, Acoramidis, FDA Approval, ATTR-CM, Transthyretin Cardiac Amyloidosis, BridgeBio Pharma, Heart Disease Treatment
Advancements in Hematology: Shaping the Future of Blood Disorder Diagnosis and Treatment
Hematology, Blood Disorders, Sickle Cell Disease, Gene Therapy, Clinical Guidelines, Quality Improvement